Synjardy has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance. 

Synjardy combines empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride, commonly prescribed for the treatment of T2D. Empagliflozin was approved in the EU in May 2014 and is available in many countries as an oral, once-daily tablet, marketed as Jardiance.

Synjardy is indicated for use alongside diet and exercise to improve blood glucose control in adults with T2D when they are:

• Inadequately controlled on their maximally tolerated dose of metformin hydrochloride alone
• Inadequately controlled with metformin hydrochloride in combination with other glucose-lowering medicinal products, including insulin
• Already being treated with the combination of empagliflozin and metformin hydrochloride as separate tablets

For more details, go to: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/28_may_2015_diabetes.html